Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$117.48

-0.03 (-0.03%)

, SNAP

Snap

$11.28

-0.71 (-5.92%)

10:12
04/24/19
04/24
10:12
04/24/19
10:12

Fly Intel: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Eli Lilly (LLY) upgraded to Buy from Hold at Edward Jones. 2. Snap (SNAP) upgraded to In Line from Underperform at Evercore ISI and to Neutral from Underweight at JPMorgan. 3. Best Buy (BBY) upgraded to Buy from Hold at Jefferies with analyst Jonathan Matuszewski saying survey and data work suggest Best Buy's greater push toward services will drive long-term value and customer wallet share. 4. Procter & Gamble (PG) upgraded to Overweight from Equal Weight at Barclays with analyst Lauren Lieberman saying the market is shrugging off Procter & Gamble's 5% organic sales growth in its fiscal Q3, with many investors thinking this is the best it can get. 5. Sonoco (SON) upgraded to Buy from Hold at Argus with analyst David Coleman saying the stock has outperformed over the past 3 months, benefiting from its "accretive acquisitions, favorable pricing, improvements in productivity, and a lower effective tax rate." This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

LLY

Eli Lilly

$117.48

-0.03 (-0.03%)

SNAP

Snap

$11.28

-0.71 (-5.92%)

BBY

Best Buy

$74.99

1.39 (1.89%)

PG

Procter & Gamble

$103.85

0.66 (0.64%)

SON

Sonoco

$62.34

1.025 (1.67%)

  • 24

    Apr

  • 25

    Apr

  • 30

    Apr

  • 04

    May

  • 06

    May

  • 07

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 18

    May

  • 23

    May

  • 29

    May

  • 18

    Jul

  • 17

    Oct

LLY Eli Lilly
$117.48

-0.03 (-0.03%)

04/11/19
04/11/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Chipotle (CMG) downgraded to Hold from Buy at Jefferies with analyst Andrew Barish saying after rallying 65% in Q1, Chipotle's valuation is full and reflects improved visibility for "powerful" same-store-sales and margin drivers. 2. Eli Lilly (LLY) downgraded to Neutral from Buy at Guggenheim with analyst Seamus Fernandez saying while he expects updates at the American Diabetes Association meeting to be broadly positive, he sees limited upside for the stock from current levels until Lilly's overall immunology portfolio and competition from Novo Nordisk's (NVO) semaglutide franchise is more fully understood. 3. U.S. Steel (X) downgraded to Underperform from Buy at BofA/Merrill with analyst Timna Tanners citing worse near-term U.S. market conditions than she anticipated. 4. Keurig Dr Pepper (KDP) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Dara Mohsenian saying she sees a negative risk-reward despite a "well telegraphed" Q1 earnings beat on strong pricing at heritage Dr. Pepper Snapple. 5. Waste Management (WM) downgraded to Hold from Buy at Stifel with analyst Michael Hoffman saying he factors in incrementally weaker paper prices and the impact of wet weather. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/18/19
PIPR
04/18/19
NO CHANGE
PIPR
Teva gains ground on Amgen in latest migraine survey, says Piper Jaffray
Following of survey of 99 neurologists done by his firm's partner Spherix Global Insights, Piper Jaffray analyst Christopher Raymond maintains an Overweight rating on Amgen (AMGN) and a Neutral rating on Teva Pharmaceutical (TEVA). The migraine survey indicates Eli Lilly's (LLY) Emgality is lagging and that Teva's Ajovy appears to be gaining ground on Amgen's Aimovig across numerous metrics, Raymond tells investors in a research note. While one data point does not a trend make, this move warrants close attention, especially given the increased significance assigned to Aimovig with respect to Amgen sentiment, says the analyst. Raymond, however, remains cautious on Teva shares given the" lack of clarity regarding when/where EBITDA will hit a trough." On the R&D side, the analyst notes that Overweight-rated Alder Biopharmaceuticals' (ALDR) eptinezumab "appears to be particularly top-of-mind among migraine specialists."
04/22/19
BMOC
04/22/19
NO CHANGE
Target $130
BMOC
Outperform
Eli Lilly price target lowered to $130 from $134 at BMO Capital
BMO Capital analyst Alex Arfaei lowered his price target on Eli Lilly to $130, saying the stock has underperformed along with its peers, and the news around its Tanezumab announced last week was "obviously negative". The analyst is keeping his Outperform rating however and believes that risk-reward on Eli Lilly is still "attractive" based on his "higher forecasts for Trulicity, Taltz, and Jardiance", as well as expectations around "improved margins". Arfaei adds that the company's upcoming REWIND data at the American Diabetes Association summit could be the "next major catalyst" for Eli Lilly shares.
04/23/19
EDJN
04/23/19
UPGRADE
EDJN
Buy
Eli Lilly upgraded to Buy from Hold at Edward Jones
Edward Jones analyst Ashtyn Evans upgraded Eli Lilly to Buy from Hold.
SNAP Snap
$11.28

-0.71 (-5.92%)

04/24/19
RHCO
04/24/19
NO CHANGE
Target $11
RHCO
Hold
Snap price target raised to $11 from $8 at SunTrust
SunTrust analyst Youssef Squali raised his price target on Snap to $11 after its "better than expected" Q1 results with a beat on revenue and earnings, positive user trends, and above-consensus guidance for Q2. The analyst cites increasing advertiser adoption and greater reach into key demographic but keeps his Hold rating on the stock, stating that the company still has "much left to do on product execution, monetization, user growth, and sustained cost containment to achieve profitability."
04/24/19
RBCM
04/24/19
NO CHANGE
Target $17
RBCM
Outperform
Snap revenue accelerated in Q1, says RBC Capital
RBC Capital analyst Mark Mahaney kept his Outperform rating and $17 price target on Snap, citing the company's Q1 earnings beat and accelerated 39% revenue growth while noting that its outlook for Q2 suggests a similar rate of growth. The analyst adds that while the management was "somewhat cautious" on daily active user trends for Q2, this could be due to its "conservatism" in guidance. Mahaney contends that his Upgrade call on Snap earlier this month is being confirmed with the quarter's fundamentals - revenue, DAUs, gross margin, EBITDA, free cash flow - all showing improvement.
04/24/19
SBSH
04/24/19
NO CHANGE
Target $14
SBSH
Neutral
Snap results encouraging, but valuation 'appears full,' says Citi
Citi analyst Mark May views Snap's Q1 results as encouraging, but adds its outlook "was more mixed." While the Q2 revenue guidance was only in-line with consensus at the midpoint and adjusted EBITDA was below, the company has recently topped its guidance, which could suggest upside to forecasts, May tells investors in a post-earnings research note. The analyst, however, believes Snap's valuation "appears full." He raised his price target for the shares to $14 from $13 and keeps a Neutral rating on the name.
04/24/19
JEFF
04/24/19
NO CHANGE
Target $13
JEFF
Hold
Snap shares already reflect Q1 improvements, says Jefferies
Jefferies analyst Brent Thill raised his price target for Snap to $13 from $11 but keeps a Hold rating on the shares following the company's Q1 results. Snap returned to user growth while also driving an acceleration of average revenue per user growth, Thill tells investors in a post-earnings research note. The analyst likes the trajectory of the business but believes the stock "already reflects these improvements."
BBY Best Buy
$74.99

1.39 (1.89%)

04/24/19
JEFF
04/24/19
UPGRADE
Target $88
JEFF
Buy
Jefferies upgrades Best Buy on services push with $88 price target
Jefferies analyst Jonathan Matuszewski upgraded Best Buy to Buy from Hold and raised his price target for the shares to $88 from $72. Survey and data work suggest Best Buy's greater push toward services will drive long-term value and customer wallet share, Matuszewski tells investors in a research note. The analyst now has increased confidence in the company's In-Home Advisor initiative and the "upward trajectory of high-margin services that it feeds," including Total Tech Support. Matuszewski also thinks the consumer electronics cycle will be stronger than many believe and that Best Buy is well positioned to capitalize. After analyzing the company's share of voice for top consumer electronics products and phrases, the analyst believes "outsized share gains lie ahead, especially as pricing versus peers improves.
04/01/19
BTIG
04/01/19
DOWNGRADE
BTIG
Neutral
Care.com downgraded to Neutral from Buy at BTIG
BTIG analyst Marvin Fong downgraded Care.com (CRCM) to Neutral from Buy citing the fallout from the Wall Street Journal's reporting on the company. The stock closed the trading day down 7%, or $1.31, to $18.45. The analyst sees "tangible fallout" after learning that Best Buy (BBY) has suspended its back-up care offering provided by Care.com's [email protected] unit. Fong, however, emphasizes that Best Buy has suspended the service, not terminated it. Best Buy told the analyst, "We are doing our due diligence to make sure Care.com is still a good choice for this benefit." While Best Buy could reinstate [email protected] at any time, it is prudent to trim [email protected] estimates to "reflect the current reality," Fong tells investors in a research note. He believes Best Buy's decision may impact the future trajectory of Care.com's back-up care business. Further, the Journal has made Care.com a "favorite target" with three articles within the span of about three weeks, says Fong. Given the importance of reputation to Care.com's model, the risks to the stock "are becoming increasingly difficult to assess with confidence," contends the analyst. While [email protected] is just 9% of the company's revenue, it accounted for 25% of its growth in 2018, he points out.
04/01/19
SBSH
04/01/19
UPGRADE
Target $18
SBSH
Neutral
Bed Bath & Beyond upgraded to Neutral from Sell at Citi
Citi analyst Geoff Small upgraded Bed Bath & Beyond (BBBY) to Neutral from Sell and raised his price target for the shares to $18 from $10 after taking over coverage of the name. Citi transferred coverage of Broadlines & Hardlines Retail names to Small. The analyst assumed coverage with Buy ratings on AutoZone (AZO), BJ's Wholesale (BJ), Home Depot (HD), Lowe's (LOW), O'Reilly Automotive (ORLY) and Walmart (WMT). The U.S. consumer remains on "solid footing" amid low unemployment, rising wages, declining gas prices, manageable levels of debt, and elevated consumer confidence, Small tells investors in a research note. However, he points out that we are in the ninth year of the current economic expansion and "the possibility of a macroeconomic slowdown cannot be ignored." The analyst prefers retailers operating in "defensive sectors that are less susceptible to disruption by online competitors," namely auto parts, broadlines and home improvement retail. Small also assumed Advance Auto Parts (AAP), Best Buy (BBY), Costco (COST) and Office Depot (ODP) with Neutral ratings.
04/24/19
JEFF
04/24/19
UPGRADE
Target $88
JEFF
Buy
Best Buy upgraded to Buy from Hold at Jefferies
Jefferies analyst Jonathan Matuszewski upgraded Best Buy to Buy from Hold and raised his price target for the shares to $88 from $72.
PG Procter & Gamble
$103.85

0.66 (0.64%)

04/24/19
UBSW
04/24/19
NO CHANGE
Target $102
UBSW
Neutral
Procter & Gamble price target raised to $102 from $95 at UBS
UBS analyst Steven Strycula raised his price target on Procter & Gamble (PG) to $102, saying that yesterday's sell-off on investor concerns about the company's ability to boost margin "overlooks" the "upcoming inflection". The analyst keeps his Neutral rating, but notes that the Q3 margin pressure was "transitory" as it was impacted by adverse FX, commodities, higher bonus, and Merck (MRK) integration headwinds.
04/24/19
DZBN
04/24/19
DOWNGRADE
DZBN
Sell
Procter & Gamble downgraded to Sell from Hold at DZ Bank
04/24/19
LEHM
04/24/19
UPGRADE
Target $112
LEHM
Overweight
Procter & Gamble upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Lauren Lieberman upgraded Procter & Gamble to Overweight from Equal Weight and raised her price target for the shares to $112 from $94.
04/24/19
LEHM
04/24/19
UPGRADE
Target $112
LEHM
Overweight
Barclays upgrades Procter & Gamble to Overweight, boosts target to $112
Barclays analyst Lauren Lieberman upgraded Procter & Gamble to Overweight from Equal Weight and raised her price target for the shares to $112 from $94. The market is shrugging off Procter & Gamble's 5% organic sales growth in its fiscal Q3, with many investors thinking this is the best it can get, Lieberman tells investors in a research note. The analyst, however, does not think it is. Unlike in past years when Procter & Gamble lost share in a growing market environment, the company is finally at a point where it is driving category growth and gaining share on a global basis, says the analyst. She believes P&G can both step up reinvestment and deliver high-single digit operating profit growth in fiscal 2020.
SON Sonoco
$62.34

1.025 (1.67%)

08/07/18
UBSW
08/07/18
DOWNGRADE
Target $54
UBSW
Neutral
Bemis downgraded to Neutral from Buy at UBS
UBS analyst Edlain Rodriguez downgraded Bemis (BMS) to Neutral following Amcor's offer to acquire the company. The analyst raised his price target for the shares to $54 from $52, which reflects a 50/50 blend of his standalone Bemis target of $52 and the implied current deal price of $55. Rodriguez says the closest plastic packaging peers to Bemis are Sealed Air (SEE), Berry Global (BERY) and Sonoco Products (SON).
04/24/19
04/24/19
UPGRADE
Target $68

Buy
Sonoco upgraded to Buy from Hold at Argus
As previously reported, Argus analyst David Coleman upgraded Sonoco Products to Buy with a price target of $68. The analyst says the stock has outperformed over the past 3 months, benefiting from its "accretive acquisitions, favorable pricing, improvements in productivity, and a lower effective tax rate." Coleman adds that given the pullback in the stock price since the company reported below-consensus Q1 sales, Sonoco Products shares appear to be "favorably valued" at current levels.
04/16/19
VERT
04/16/19
DOWNGRADE
VERT
Sell
Sonoco downgraded to Sell from Hold at Vertical Research
04/24/19
ARGS
04/24/19
UPGRADE
ARGS
Buy
Sonoco upgraded to Buy from Hold at Argus

TODAY'S FREE FLY STORIES

T

AT&T

$32.36

0.06 (0.19%)

, CMCSA

Comcast

$42.31

0.62 (1.49%)

17:58
06/16/19
06/16
17:58
06/16/19
17:58
On The Fly
Box Office Battle: 'Men in Black: International' wins weekend with just $28.5M »

Sony’s (SNE) "Men in…

T

AT&T

$32.36

0.06 (0.19%)

CMCSA

Comcast

$42.31

0.62 (1.49%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$51.42

1.735 (3.49%)

LGF.A

Lionsgate

$12.22

-0.85 (-6.50%)

DIS

Disney

$141.64

-0.09 (-0.06%)

VIAB

Viacom

$29.38

-0.28 (-0.94%)

VIA

Viacom

$34.61

0.14 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 24

    Jul

  • 25

    Jul

  • 08

    Aug

  • 08

    Aug

GS

Goldman Sachs

$191.71

0.24 (0.13%)

17:43
06/16/19
06/16
17:43
06/16/19
17:43
Periodicals
Goldman Sachs combining private-investing units, WSJ reports »

Goldman Sachs is pulling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 16

    Jul

DB

Deutsche Bank

$6.79

-0.07 (-1.02%)

17:38
06/16/19
06/16
17:38
06/16/19
17:38
Periodicals
Deutsche Bank to set up EUR50B bad bank, Financial Times reports »

Deutsche Bank is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$87.10

(0.00%)

16:35
06/16/19
06/16
16:35
06/16/19
16:35
Periodicals
Tires blow on United jet during Newark airport landing, Reuters reports »

Tires on a United…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$87.83

-0.48 (-0.54%)

16:33
06/16/19
06/16
16:33
06/16/19
16:33
Periodicals
Target registers back online after outage blamed on tech issue, Reuters says »

Target said its payment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$46.18

-0.54 (-1.16%)

16:30
06/16/19
06/16
16:30
06/16/19
16:30
Hot Stocks
Intel announces program for Israeli startups targeting tech inflections »

Intel announced a program…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 25

    Jul

BA

Boeing

$347.19

-1.54 (-0.44%)

16:27
06/16/19
06/16
16:27
06/16/19
16:27
Periodicals
Boeing says will take time to rebuild customer confidence, Reuters reports »

The head of Boeing said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 09

    Jul

GS

Goldman Sachs

$191.71

0.24 (0.13%)

16:19
06/16/19
06/16
16:19
06/16/19
16:19
Periodicals
Goldman Sachs skeptical of 'insurance' rate cuts from Fed, Reuters says »

Goldman Sachs economists…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 16

    Jul

BA

Boeing

$347.19

-1.54 (-0.44%)

16:16
06/16/19
06/16
16:16
06/16/19
16:16
Periodicals
Trials nearing for Boeing 737 Max fix, WSJ reports »

The Federal Aviation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 09

    Jul

ESLT

Elbit Systems

$154.55

0.55 (0.36%)

13:41
06/16/19
06/16
13:41
06/16/19
13:41
Hot Stocks
Elbit Systems awarded $50M contract »

Elbit Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$176.09

-0.74 (-0.42%)

13:40
06/16/19
06/16
13:40
06/16/19
13:40
Hot Stocks
Amgen announces BLINCYTO five-year overall survival data »

Amgen announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

SILK

Silk Road Medical

$44.80

-0.95 (-2.08%)

13:35
06/16/19
06/16
13:35
06/16/19
13:35
Hot Stocks
Silk Road Medical announces final results for ROADSTER-2 study »

Silk Road Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 26

    Aug

EDIT

Editas Medicine

$21.72

-0.78 (-3.47%)

13:30
06/16/19
06/16
13:30
06/16/19
13:30
Hot Stocks
Editas presents pre-clinical data in Sickle Cell Disease, Beta-Thalassemia »

Editas Medicine announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNSS

Sunesis

$0.90

-0.055 (-5.79%)

13:28
06/16/19
06/16
13:28
06/16/19
13:28
Hot Stocks
Sunesis announces preliminary data from Phase 1b/2 trial of Vecabrutinib »

Sunesis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

APLS

Apellis

$21.22

-0.14 (-0.66%)

13:23
06/16/19
06/16
13:23
06/16/19
13:23
Hot Stocks
Apellis presents data from ongoing Phase 2 PLAUDIT study of APL-2 »

Apellis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

FTSV

Forty Seven

$10.55

-0.02 (-0.19%)

13:16
06/16/19
06/16
13:16
06/16/19
13:16
Hot Stocks
Forty Seven announces data from Phase 1b/2 trial of 5F9 in combo with Rituximab »

Forty Seven announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$39.68

-0.23 (-0.58%)

13:06
06/16/19
06/16
13:06
06/16/19
13:06
Hot Stocks
AstraZeneca announces results from interim analysis of Phase 2 ASCEND trial »

AstraZeneca announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

STRO

Sutro Biopharma

$11.17

-0.34 (-2.95%)

13:02
06/16/19
06/16
13:02
06/16/19
13:02
Hot Stocks
Sutro Biopharma announces interim Phase 1 safety data for STRO-001 »

Sutro Biopharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPMC

Blueprint Medicines

$90.65

-0.35 (-0.38%)

12:59
06/16/19
06/16
12:59
06/16/19
12:59
Hot Stocks
Blueprint Medicines presents updated EXPLORER trial data for Avapritinib »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

INCY

Incyte

$77.76

1.385 (1.81%)

12:52
06/16/19
06/16
12:52
06/16/19
12:52
Hot Stocks
Incyte announced results from Phase 2 study of Ruxolitinib cream in vitiligo »

Incyte announces 24-week…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

, INCY

Incyte

$77.76

1.385 (1.81%)

04:55
06/16/19
06/16
04:55
06/16/19
04:55
Conference/Events
European Hematology Association to hold a conference »

24th EHA Congress 2019…

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

INCY

Incyte

$77.76

1.385 (1.81%)

ARQL

ArQule

$8.17

1.88 (29.89%)

AMGN

Amgen

$176.09

-0.74 (-0.42%)

ALXN

Alexion

$117.94

0.65 (0.55%)

AGIO

Agios Pharmaceuticals

$47.97

-1.78 (-3.58%)

AZN

AstraZeneca

$39.68

-0.23 (-0.58%)

BLUE

Bluebird Bio

$117.57

-6.33 (-5.11%)

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

CELG

Celgene

$96.49

0.07 (0.07%)

NVS

Novartis

$89.52

-0.07 (-0.08%)

NSTG

NanoString

$25.96

0.45 (1.76%)

KPTI

Karyopharm

$5.71

-0.04 (-0.70%)

JAZZ

Jazz Pharmaceuticals

$130.43

0.28 (0.22%)

GSK

GlaxoSmithKline

$40.12

0.015 (0.04%)

GILD

Gilead

$66.38

-0.62 (-0.93%)

DSNKY

Daiichi Sankyo

$0.00

(0.00%)

PFE

Pfizer

$42.75

0.24 (0.56%)

PTLA

Portola Pharmaceuticals

$25.78

-0.31 (-1.19%)

QGEN

Qiagen

$39.52

-0.07 (-0.18%)

RHHBY

Roche

$0.00

(0.00%)

RIGL

Rigel Pharmaceuticals

$2.06

-0.06 (-2.83%)

SNY

Sanofi

$42.46

-0.225 (-0.53%)

SGEN

Seattle Genetics

$68.67

-0.33 (-0.48%)

STML

Stemline

$14.20

0.12 (0.85%)

VSTM

Verastem

$1.39

0.125 (9.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 18

    Jun

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 21

    Jun

  • 23

    Jun

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 27

    Jun

  • 28

    Jun

  • 28

    Jun

  • 06

    Jul

  • 25

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 26

    Aug

  • 28

    Aug

  • 29

    Aug

  • 02

    Sep

  • 03

    Sep

  • 16

    Sep

  • 04

    Nov

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

, GRUB

GrubHub

$70.15

-2.76 (-3.79%)

13:28
06/15/19
06/15
13:28
06/15/19
13:28
Periodicals
Amazon exit gives GrubHub stock boost, Barron's says »

Amazon (AMZN) is…

AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

GRUB

GrubHub

$70.15

-2.76 (-3.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 10

    Jul

ABC

AmerisourceBergen

$85.01

-1.46 (-1.69%)

, CAH

Cardinal Health

$44.16

-1.13 (-2.50%)

13:20
06/15/19
06/15
13:20
06/15/19
13:20
Periodicals
McKesson, Cardinal Health looking like bargains, Barron's says »

Investors have halved the…

ABC

AmerisourceBergen

$85.01

-1.46 (-1.69%)

CAH

Cardinal Health

$44.16

-1.13 (-2.50%)

MCK

McKesson

$133.19

-1.7 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

RTN

Raytheon

$177.38

0.195 (0.11%)

, UTX

United Technologies

$125.30

0.45 (0.36%)

13:09
06/15/19
06/15
13:09
06/15/19
13:09
Periodicals
United Technologies, Raytheon stocks looking cheap, Barron's says »

Shares of United…

RTN

Raytheon

$177.38

0.195 (0.11%)

UTX

United Technologies

$125.30

0.45 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 17

    Jun

  • 17

    Jun

GRUB

GrubHub

$70.15

-2.76 (-3.79%)

, AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

13:04
06/15/19
06/15
13:04
06/15/19
13:04
Periodicals
Food fight extending well beyond restaurant delivery, Barron's says »

Amazon (AMZN) is quitting…

GRUB

GrubHub

$70.15

-2.76 (-3.79%)

AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 10

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.